Expiration dating of pontocaine rules dating your neighbor
LET solution consists of lidocaine HCl USP 4%, epinephrine bitartrate USP 180 mg, and tetracaine HCl USP 500 mg, with sodium metabisulfite 75 mg in sterile water for irrigation USP to 100 m L.It was described as a replacement for the problematic, traditional, cocaine-containing TAC solution by Schilling et al in 1995 (Schilling CG, Bank DE, Borchert BA, Klatzko MD, Uden DL. no statistical difference between TAC and LET in adequacy of anesthesia before suturing or in duration of anesthesia during suturing."This result led them to conclude that LET could replace TAC effectively in the emergency room for use while suturing uncomplicated lacerations. Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.
There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion.
All information in the Formulary is provided as a reference for drug therapy selection.
Physicians and pharmacists are encouraged to review the Formulary and utilize it when prescribing for our members.
Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%.
Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition.